

## Listes des Publications 2014 et 2016 Gilles Edan

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, **Edan G**, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group : [Sodium intake and multiple sclerosis activity and progression in BENEFIT](#).  
Ann Neurol. 2017 Jul; 82(1):20-29

Le Page E, **Edan G** : [Oral rather than intravenous corticosteroids should be used to treat MS relapses - Yes](#).  
Mult Scler. 2017 Jul;23(8):1056-1058

Kalson-Ray S, **Edan G**, Leray E; SURVIMUS Study Group. : [An excessive risk of suicide may no longer be a reality for multiple sclerosis patients](#).  
Mult Scler. 2017 May;23(6):864-871.

Fernández O, Delvecchio M, **Edan G**, Fredrikson S, Gionvannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G. : [Survey of diagnostic and treatment practices for multiple sclerosis in Europe](#).  
Eur J Neurol. 2017 Mar;24(3):516-522.

**Edan G**, Kerbrat A. : [Inhibitor of Fatty Acid Amide Hydrolase - Learning from Tragic Failures](#).  
N Engl J Med. 2017 Jan 26;376(4):393-4.

Pivot D, Debouverie M, Grzebyk M, Brassat D, Clanet M, Clavelou P, Confavreux C, **Edan G**, Leray E, Moreau T, Vukusic S, Hédelin G, Guillemin F.: [Geographical Heterogeneity of Multiple Sclerosis Prevalence in France](#).  
PLoS One. 2016 Dec 9;11(12):e0167556.

Kerbrat A, Ferré JC, Fillatre P, Ronzière T, Vannier S, Carsin-Nicol B, Lavoué S, Vérin M, Gauvrit JY, Le Tulzo Y, **Edan G** : [Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase](#).  
N Engl J Med. 2016 Nov 3;375(18):1717-1725.

Bonenfant J, Bajoux E, Deburghgraeve V, Le Page E, **Edan G**, Kerbrat A. : [Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis ?](#)  
Eur J Neurol. 2017 Feb;24(2):237-244.

Tourbah A, Lebrun-Frenay C, **Edan G**, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group. : [MD1003 \(high-dose biotin\) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study](#).  
Mult Scler. 2016 Nov;22(13):1719-1731.

Kappos L, **Edan G**, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.: [The 11-year long-term follow-up study from the randomized BENEFIT CIS trial](#).  
Neurology. 2016 Sep 6;87(10):978-87.

Maarouf A, Ferré JC, Zaaoui W, Le Troter A, Bannier E, Berry I, Guye M, Pierot L, Barillot C, Pelletier J, Tourbah A, **Edan G**, Audoin B, Ranjeva JP. : [Ultra-small superparamagnetic iron oxide enhancement is associated with higher loss of brain tissue structure in clinically isolated syndrome](#).  
Mult Scler. 2015 Oct 9

Munger KL, Fitzgerald KC, Freedman MS, Hartung HP, Miller DH, Montalbán X, **Edan G**, Barkhof F, Suarez G, Radue EW, Sandbrink R, Kappos L, Pohl C, Ascherio A. : [No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT](#).  
Neurology. 2015 Nov 10;85(19):1694-701.

Gonsette R, Debouverie M, Sindic C, Ferré JC, **Edan G** : [Plixantone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease](#).  
Mult Scler. 2015 Aug 18. pii: 1352458515601902.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Sèze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, **Edan G** : [Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study](#).

PLoS One. 2015 Jul 6;10(7):e0132033.

Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, **Edan G**; COPOUSEP investigators; West Network for Excellence in Neuroscience. : [Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis \(COPOUSEP\): a randomised, controlled, double-blind, non-inferiority trial.](#)

Lancet. 2015 Sep 5;386(9997):974-81

Commowick O, Maarouf A, Ferré JC, Ranjeva JP, **Edan G**, Barillot C. : [Diffusion MRI abnormalities detection with orientation distribution functions: a multiple sclerosis longitudinal study.](#)

Med Image Anal. 2015 May;22(1):114-23.

Le Page E, Deburghgraeve V, Lester MA, Cardiet I, Leray E, **Edan G**. : [Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.](#)

J Neurol. 2015;262(4):1024-34.

Caucheteux N, Maarouf A, Genevray M, Leray E, Deschamps R, Chaunu MP, Daelman L, Ferré JC, Gout O, Pelletier J, Pierot L, **Edan G**, Tourbah A. : [Criteria improving multiple sclerosis diagnosis at the first MRI.](#)

J Neurol. 2015;262(4):979-87.

Cotton F, Kremer S, Hannoun S, Vukusic S, Dousset V; Imaging Working Group of the Observatoire Français de la Sclérose en Plaques. : [OFSEP, a nationwide cohort of people with multiple sclerosis: Consensus minimal MRI protocol.](#)

J Neuroradiol. 2015 Jun;42(3):133-40

Kerbrat A, Hamonic S, Leray E, Tron I, **Edan G**, Yaouanq J; West Neuroscience Network of Excellence (WENNE). : [Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.](#)

Eur J Neurol. 2015 Mar;22(3):507-e35

Yaouanq J, Tron I, Kerbrat A, Leray E, Hamonic S, Merienne M, Hinault P, **Edan G**. : [Register-based incidence of multiple sclerosis in Brittany \(north-western France\), 2000-2001.](#)

Acta Neurol Scand. 2015 May;131(5):321-8.

Devy R, Leheret P, Varlan E, Genty M, **Edan G**. : [Improving the quality of life of multiple sclerosis patients through coping strategies in routine medical practice.](#)

Neurol Sci. 2015 Jan;36(1):85-90.

Crimi A, Commowick O, Maarouf A, Ferré JC, Bannier E, Tourbah A, Berry I, Ranjeva JP, **Edan G**, Barillot C. : [Predictive value of imaging markers at multiple sclerosis disease onset based on gadolinium- and USPIO-enhanced MRI and machine learning.](#)

PLoS One. 2014 Apr 1;9(4):e93024.

Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, **Edan G**, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C. : [Vitamin D as an early predictor of multiple sclerosis activity and progression.](#)

JAMA Neurol. 2014 Mar;71(3):306-14.

**Edan G**, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D; BENEFIT Study Group. : [Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.](#)

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9